AR127806A1 - Anticuerpos b7-h4 y proteínas de fusión de anticuerpo b7-h4 / il-15 - Google Patents
Anticuerpos b7-h4 y proteínas de fusión de anticuerpo b7-h4 / il-15Info
- Publication number
- AR127806A1 AR127806A1 ARP220103274A ARP220103274A AR127806A1 AR 127806 A1 AR127806 A1 AR 127806A1 AR P220103274 A ARP220103274 A AR P220103274A AR P220103274 A ARP220103274 A AR P220103274A AR 127806 A1 AR127806 A1 AR 127806A1
- Authority
- AR
- Argentina
- Prior art keywords
- fusion proteins
- antibodies
- antigen
- binding
- antibody
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title abstract 5
- 108020001507 fusion proteins Proteins 0.000 title abstract 5
- 239000000427 antigen Substances 0.000 abstract 5
- 102000036639 antigens Human genes 0.000 abstract 5
- 108091007433 antigens Proteins 0.000 abstract 5
- 239000012634 fragment Substances 0.000 abstract 5
- 238000000034 method Methods 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000014914 Carrier Proteins Human genes 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 108091008324 binding proteins Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Se proporcionan anticuerpos recombinantes, fragmentos de unión a antígeno de los mismos y proteínas de fusión de los mismos útiles para unirse a B7-H4 e inhibirlo. También se proporcionan moléculas de ácido nucleico que codifican los anticuerpos, los fragmentos de unión a antígeno de los mismos y las proteínas de fusión de los mismos descritos en la presente memoria y las composiciones terapéuticas de los mismos. Se describen otros métodos de uso de los anticuerpos descritos, sus fragmentos de unión a antígeno y sus proteínas de fusión para el tratamiento de enfermedades. Reivindicación 66: Un vector que comprende el ácido nucleico de la reivindicación 66. Reivindicación 70: Una célula T que expresa una proteína de unión a anti-B7-H4 que comprende las cadenas variables pesada y ligera del anticuerpo anti-B7-H4, o un fragmento de unión a antígeno del mismo, de cualquiera de las reivindicaciones 1 - 33. Reivindicación 94: Un método para detectar B7-H4 en una muestra, el método comprende poner en contacto la muestra con el anticuerpo anti-B7-H4, o fragmento de unión a antígeno del mismo, de cualquiera de las reivindicaciones 1 - 33 o la proteína de fusión de cualquiera de las reivindicaciones 34 - 65.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163284937P | 2021-12-01 | 2021-12-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR127806A1 true AR127806A1 (es) | 2024-02-28 |
Family
ID=84519919
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP220103274A AR127806A1 (es) | 2021-12-01 | 2022-11-29 | Anticuerpos b7-h4 y proteínas de fusión de anticuerpo b7-h4 / il-15 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20230312724A1 (es) |
AR (1) | AR127806A1 (es) |
TW (1) | TW202346320A (es) |
WO (1) | WO2023102367A1 (es) |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69333807T2 (de) | 1992-02-06 | 2006-02-02 | Chiron Corp., Emeryville | Marker für krebs und biosynthetisches bindeprotein dafür |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
ES2861435T3 (es) * | 2011-11-03 | 2021-10-06 | Univ Pennsylvania | Composiciones específicas de B7-H4 aisladas y métodos de uso de las mismas |
JP2016509582A (ja) | 2012-12-19 | 2016-03-31 | アンプリミューン, インコーポレイテッド | 抗ヒトb7−h4抗体およびその使用 |
PL3094351T3 (pl) * | 2014-01-15 | 2022-06-27 | Kadmon Corporation, Llc | Środki immunomodulujące |
AR101848A1 (es) * | 2014-09-12 | 2017-01-18 | Genentech Inc | Anticuerpos de anti-b7-h4 e inmunoconjugados |
US11306144B2 (en) | 2017-08-25 | 2022-04-19 | Five Prime Therapeutics, Inc. | B7-H4 antibodies and methods of use thereof |
EP3728705A4 (en) * | 2017-12-18 | 2022-01-19 | Charles River Laboratories, Inc. | RADICALLY DIVERSE HUMAN ANTIBODY BANK |
KR20200119846A (ko) * | 2018-02-11 | 2020-10-20 | 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 | 항 비7 에이치4 항체, 그의 항원 결합 단편 및 그의 약학적 용도 |
JP2021516045A (ja) * | 2018-02-28 | 2021-07-01 | ファイザー・インク | Il−15バリアントおよびその使用 |
-
2022
- 2022-11-29 AR ARP220103274A patent/AR127806A1/es unknown
- 2022-11-29 US US18/059,548 patent/US20230312724A1/en active Pending
- 2022-11-29 TW TW111145737A patent/TW202346320A/zh unknown
- 2022-11-29 WO PCT/US2022/080542 patent/WO2023102367A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
TW202346320A (zh) | 2023-12-01 |
WO2023102367A1 (en) | 2023-06-08 |
US20230312724A1 (en) | 2023-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112021024540A2 (pt) | Métodos para selecionar uma célula ou um vírus, determinar a sequência de um ácido nucleico, produzir uma célula que expressa um ácido nucleico e tratar um sujeito, célula imune selecionada e método para selecionar uma célula imune | |
CL2018001827A1 (es) | Proteína de unión de tipo anticuerpo con región variable dual que comprende cuatro cadenas polipeptídicas que forman cuatro sitios de unión a antígeno; molécula de ácido nucleico que la codifica; vector de expresión; célula; método de elaboración; y composición farmacéutica que la comprende (divisional solicitud 201302763) | |
CY1122435T1 (el) | Ποντικοι με εξανθρωπισμενη καθολικη ελαφρια αλυσιδα | |
CY1120951T1 (el) | Ανθρωπινα αντισωματα enanti-tau | |
BR112018070823A2 (pt) | anticorpo sirpa anti-humano ou fragmento de ligação a antígeno do mesmo ou mimético de anticorpo de ligação a antígeno, composição farmacêutica, produto de combinação, molécula de ácido nucleico isolada, vetor, célula hospedeira isolada, polipeptídeo, métodos para fabricar um anticorpo, in vitro ou ex vivo para determinar células positivas para sirpa, de diagnóstico e para prever a resposta de um sujeito, e, uso de um anticorpo anti-sirpa ou um fragmento de ligação a antígeno do mesmo ou um mimético de ligação a anticorpo e in vitro ou ex vivo de pelo menos um anticorpo sirpa anti-humano ou fragmento de ligação a antígeno do mesmo ou mimético de anticorpo de ligação a antígeno. | |
CY1119647T1 (el) | Αντισωματα προσδεσης αλβουμινης και τμηματα προσδεσης αυτων | |
PE20150023A1 (es) | Proteinas de union a antigeno st2 | |
AR077088A1 (es) | Proteinas biespecificas de union a antigeno | |
AR109451A1 (es) | Composiciones y métodos para preparar anticuerpos basados en el uso de loci mejoradores de expresión | |
AR093984A1 (es) | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano | |
PE20091172A1 (es) | Anticuerpos bivalentes biespecificos | |
DK1787126T3 (da) | Fremgangsmåde til karakterisering af en polyklonal cellelinie | |
EA201491599A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
ES2639026T3 (es) | Anticuerpos totalmente humanos específicos para CADM1 | |
EA201171259A1 (ru) | Антительные гибридные белки с модифицированными сайтами связывания fcrn | |
ATE504602T1 (de) | Für humane matriptase spezifische bindungsproteine | |
UY38672A (es) | Anticuerpo monoclonal que se une específicamente a gitr | |
ECSP18084153A (es) | Anticuerpos anti-BASIGIN humanizados y uso de los mismos | |
CY1110461T1 (el) | Αναλυση της τυποποιησης μονοκλωνικων πρωτεϊνων με τριχοειδη ηλεκτροφορηση και ανοσομετατοπιση | |
AR123997A1 (es) | ANTICUERPOS NEUTRALIZANTES CONTRA EL SARS-CoV-2 | |
CL2023001888A1 (es) | Anticuerpos multiespecíficos con especificidad para il-4r e il-31. | |
AR102095A1 (es) | Método para medir la reactividad del fviii | |
PE20181498A1 (es) | Anticuerpos monoclonales especificos para el antigeno piii de adenovirus humano (adv), producidos y secretados por hibridomas celulares, utiles para la deteccion y el diagnostico de la infeccion causada por adv | |
AR127806A1 (es) | Anticuerpos b7-h4 y proteínas de fusión de anticuerpo b7-h4 / il-15 | |
UY38807A (es) | Proteínas de unión a antígeno anti-il13 |